bold = Main text
   Part, Chapter, Paragraph                                   grey = Comment text

 1 I, 1,1      |                                              1.~ To date, there is only
 2 I, 2,2      |                     sugar moiety, the Gal-a (1,3)-Gal-ß (1,4)-GlcNac antigens
 3 I, 2,2      |                       the Gal-a (1,3)-Gal-ß (1,4)-GlcNac antigens of the
 4 I, 2,2(16)  |                     complement receptor type 1 on hyperacute rejection
 5 I, 2,2      |                     pigs by knocking out the 1,3 galactosyl transferase
 6 I, 2,2(18)  |                humans, Nature Medicine 1995, 1: 964-6; Fodor W.L., Williams
 7 I, 2,2(18)  |                     injury, Nature Med 1995, 1: 423-7; Cowan P.J., Aminian
 8 I, 2,2(19)  |             cytolysis, Nature Medicine 1995, 1: 1261-7. ~
 9 I, 2,3(30)  |              xenografts, J Immunol. 1999 Sep 1; 163(5): 2850-7. ~
10 I, 2,3(33)  |                     injury, Nature Med 1995, 1: 423-7; Cozzi E., Yannoutsos
11 I, 2,3(34)  |                     injury, Nature Med 1995, 1: 423-7. ~
12 II, 1       |                      to xenotransplantation: 1) the acceptability of man'
13 II, 1,7     |                    earth and subdue it" (Gen 1: 28):  this is the mandate
14 II, 1,7(50) |    theological-liturgical nature, used in Gn 1: 1-31; for a fuller understanding
15 II, 1,7(50) | theological-liturgical nature, used in Gn 1: 1-31; for a fuller understanding
16 II, 1,7(50) |                account of creation, in Gn 2: 1-25, must also be taken into
17 II, 1,9     |                    likeness of God" (cf. Gen 1: 26-27), we reaffirm that
18 II, 1,12(63)|                    di Giovanni Paolo II, XIV/1, 1991, p. 1711, 20/6/1991;
19 II, 2,15    |                   which must be respected:  ~1. Concern for the well-being
20 II, 2,16(70)|                   Health Care Philos 2001, 4(1): 53-70. ~